Menlo Park, Calif.-based Cogentus Pharmaceuticals has filed for Chapter 7 bankruptcy, despite $83 million raised in equity capital. At the time of the filing, the company reported $2.2 million in assets and liabilities totaling $17.2 million.

The company was just about to launch third-phase clinical trials on its lead drug candidate, an anti-platelet therapy used to treat cardiovascular disease. The trial was expected to enroll 4,000 patients in the U.S., South America, Canada and Europe.

Congentus’ backers included Keffi Group, Prospect Venture Partners, Pinnacle Ventures, Ridgeback Capital and Apothecary Capital. Three of these contributors, Keffi, Prospect and Ridgeback are each owed $500,000 from convertible debt investments, according to VentureWire. Prospect had a nearly 50 percent stake in the company. Another major creditor, Parexel International, is owed $13.9 million for clinical services its employees performed for the firm.


VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member